Literature DB >> 25402571

Impact of corneal cross-linking on topical drug penetration in humans.

Christoph Tappeiner1, Markus Tschopp1, Kaspar Schuerch1, Beatrice E Frueh1.   

Abstract

PURPOSE: To analyse the influence of corneal cross-linking (CXL) with ultraviolet-A (UV-A) and riboflavin on drug permeability in human subjects.
METHODS: Keratoconus patients (n = 23; mean age 26.9 ± 5.8 years) undergoing a standard CXL procedure with UV-A (5.4 J/cm(2) , 30 min) and riboflavin in one eye were included in the study. The pupillary diameter, measured before and every 3 min for 30 min after the topical application of one drop of 2% pilocarpine, was used as an indirect measure of the corneal permeability. The pupillary diameter was measured with an infrared pupillometer device before (baseline) and 4 months after CXL.
RESULTS: Prior to pilocarpine application, no significant difference in the pupillary diameter was detected before CXL and 4 months later. The mean decrease in the pupillary diameter after the application of pilocarpine was similar at baseline and the 4-month follow-up visit: mean decreases of 3.9 and 3.7 mm were observed 30 min after pilocarpine application, respectively (p > 0.05).
CONCLUSIONS: No significant influence of CXL on the corneal penetration of topically applied pilocarpine was observed in this clinical study.
© 2014 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  cornea; corneal cross-linking; drug penetration; in vivo; keratoconus; pilocarpine; pupillometry

Mesh:

Substances:

Year:  2014        PMID: 25402571     DOI: 10.1111/aos.12595

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN: 1755-375X            Impact factor:   3.761


  1 in total

1.  A study of stromal riboflavin absorption in ex vivo porcine corneas using new and existing delivery protocols for corneal cross-linking.

Authors:  Sally Hayes; Siân R Morgan; David P O'Brart; Naomi O'Brart; Keith M Meek
Journal:  Acta Ophthalmol       Date:  2015-09-30       Impact factor: 3.761

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.